Numerous clinical trials are exploring a diverse array of therapeutic modalities, ranging from antigen-specific therapies and immune modulators to innovative cell therapies, for disease prevention but also to preserve endogenous insulin function in individuals with newly diagnosed T1D (see Table 1 for a detailed description). This evidence concerns the gene INS and type 1 diabetes mellitus.